MediWound Advances EscharEx Trial as NexoBrid Revenue Grows
Event summary
- EscharEx Phase III VALUE trial enrollment expected to complete by Q1 2027.
- NexoBrid revenue grows under new BARDA contract with Vericel.
- Q2 2026 revenue at $3.1M, down from $5.7M in Q2 2025 due to timing of BARDA-funded development revenue.
- Full-year 2026 revenue guidance reaffirmed at $24–26 million.
The big picture
MediWound is advancing its EscharEx Phase III trial while leveraging the commercial success of NexoBrid through a strategic partnership with Vericel under BARDA's contract. The company's focus on enzymatic therapeutics for tissue repair positions it within the broader trend of non-surgical wound care innovations, though it faces challenges in balancing aggressive R&D spending with financial sustainability.
What we're watching
- Clinical Trial Progress
- The pace at which EscharEx Phase III VALUE trial enrollment completes will determine the timeline for potential regulatory approval.
- Revenue Diversification
- Whether MediWound can sustain revenue growth through government-funded programs and commercial partnerships like Vericel's BARDA contract.
- Cash Burn Management
- How effectively MediWound manages its cash burn amid increased R&D investments and operational expenses.
Related topics